Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis

Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis

Leptomeningeal metastases from solid tumors are a rare complication with a very poor prognosis. Here the authors report the efficacy and safety of combined ipilimumab and nivolumab in patients with leptomeningeal carcinomatosis.

Détails bibliographiques
Auteurs principaux:	Priscilla K. Brastianos, Matthew R. Strickland, Eudocia Quant Lee, Nancy Wang, Justine V. Cohen, Ugonma Chukwueke, Deborah Anne Forst, April Eichler, Beth Overmoyer, Nancy U. Lin, Wendy Y. Chen, Aditya Bardia, Dejan Juric, Ibiayi Dagogo-Jack, Michael D. White, Jorg Dietrich, Naema Nayyar, Albert E. Kim, Christopher Alvarez-Breckenridge, Maura Mahar, Joana L. Mora, Brian V. Nahed, Pamela S. Jones, Helen A. Shih, Elizabeth R. Gerstner, Anita Giobbie-Hurder, Scott L. Carter, Kevin Oh, Daniel P. Cahill, Ryan J. Sullivan
Format:	Article
Langue:	English
Publié:	Nature Portfolio 2021-10-01
Collection:	Nature Communications
Accès en ligne:	https://doi.org/10.1038/s41467-021-25859-y

Internet

https://doi.org/10.1038/s41467-021-25859-y